FDA Grants Priority Review for Rusfertide in Polycythemia Vera Treatment

Key Facts

1The U.S. FDA accepted the New Drug Application (NDA) for rusfertide.

2The FDA granted Priority Review for the drug as a potential treatment for polycythemia vera.

3Rusfertide is a first-in-class hepcidin mimetic peptide therapeutic.

The U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for rusfertide, a promising treatment for polycythemia vera. Developed by Protagonist Therapeutics (PTGX) in collaboration with Takeda (TAK), the drug has been granted Priority Review status by the agency. This designation significantly shortens the regulatory review period, potentially accelerating the therapy's entry into the market. Rusfertide represents a first-in-class hepcidin mimetic peptide designed to manage this rare and chronic blood disorder. The acceptance of the NDA marks a critical milestone for both companies as they seek to provide a new therapeutic option for adult patients. Investors are viewing the news as a positive catalyst, as the Priority Review underscores the clinical importance and potential impact of the treatment.